ENERGI-F703 for Diabetic Foot Ulcers Phase II Study

Energenesis Biomedical

Status and phase

Completed

Phase 2

Conditions

Diabetic Foot

Foot Ulcer

Diabetes Mellitus

Wounds

Treatments

Drug: ENERGI-F703

Drug: ENERGI-F703 matched vehicle

Study type

Interventional

Funder types

Industry

Identifiers

NCT02672436

ENERGI-F703-01

Details and patient eligibility

About

The objective of this study is to evaluate the efficacy and safety of ENERGI-F703 in subject with diabetic foot ulcers.

Enrollment

141 patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

With either gender aged at least 20 years old
With diagnosed diabetic mellitus (DM), e.g. currently under DM medication treatment or naïve DM subject with duplicated HbA1c over 6.5% and fasting plasma glucose over 126 mg/dL measured at least one week apart before Screening)
With at least one cutaneous ulcer on the foot (including ulcers on the lower legs) and not healing for at least 4 weeks. The largest diabetic foot ulcer will be selected as target ulcer. If two or more ulcers have the largest size, the one with worst grade will be selected. If two or more ulcers have the largest size and grade, the one with longest duration will be selected.
The target ulcer is classified as grade 1 to 3 ulcer according to Wagner Grading System and with ulcer size of 1 cm2 to 36 cm2 (Grade 3 ulcer subject may enter the study only if after debridement, the abscess of target ulcer is under control at investigator's discretion and osteomyelitis does not present)
Diabetic foot ulcers should be free of any necrosis or infection in any soft tissue and bone tissue;
Subject has signed the written informed consent form

Exclusion criteria

With active osteomyelitis
With target ulcer size decreased by at least 30% after at least 2 weeks of standard-of-care-only period or any other recorded regular therapy either before Screening visit or after completing Initial Phase
With poor nutritional status (albumin < 2g/dl), poor diabetic control (HbA1c > 12%), a leukocyte counts < 2,000/mm3, abnormal liver function (AST, ALT>3 x upper limit of normal range) within 14 days before Screening visit or 28 days before Randomization visit Note: HbA1c: hemoglobin A1c; AST: aspartate aminotransferase; ALT: alanine aminotransferase
Requiring treatment with systemic corticosteroids, immunosuppressive or chemotherapeutic agents
With known or suspected hypersensitivity to any ingredients of study product and vehicle
With coronary heart disease with myocardial infarction, coronary artery bypass graft (CABG), or percutaneous transluminal coronary angioplasty (PTCA) within 3 months prior to study
Pregnant or lactating or premenopausal with childbearing potential but not taking reliable contraceptive method(s) during the study period Note: Women with childbearing potential should agree to use a highly effective method of birth control, defined as those, alone or in combination, that result in a low failure rate when used consistently and correctly.
With the following conditions:
1. ankle brachial index (ABI) < 0.4 OR
2. ABI between 0.4 and 0.6 (inclusive) and not received appropriate treatment for improving venous and arterial insufficiency Note: Subjects with ABI between 0.4 and 0.6 (inclusive) and having received appropriate surgical or endovenous/endovascular therapy for improving venous and arterial insufficiency considered by investigators such as valvuloplasty, angioplasty, or bypass grafting will be eligible to enter the study at investigator's discretion.
Enrollment in any investigational drug trial within 4 weeks before entering this study
With any condition judged by the investigator that entering the trial may be detrimental to the subject